Inflammatory risk factors and pathologies promoting Alzheimer’s disease progression: Is RAGE the key?

Histology and Histopathology

Volumn 30, Issue 2, 2015, Pages 125-139

  Matrone, Carmela ^a   Djelloul, Mehdi ^b   Taglialatela, Giulio ^c   Perrone, Lorena ^d,e  

^a AARHUS UNIVERSITY   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c Department of Neuroscience and Cell Biology ^*  (United States)

^d UMUC Europe   (Germany)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Alzheimer Disease; Inflammation; RAGE; Risk factors; TXNIP

Indexed keywords

ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ALZHEIMER DISEASE; DISEASE COURSE; GENETICS; INFLAMMATION; PATHOLOGY; RISK FACTOR;

ALZHEIMER DISEASE; DISEASE PROGRESSION; INFLAMMATION; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 84920990009     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Abbas A., Aukrust P., Dahl T.B., Bjerkeli V., Sagen E.B., Michelsen A., Russell D., Krohg-Sorensen K., Holm S., Skjelland M. and Halvorsen B. (2012). High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis. Stroke 43, 1347-1353.
2. Arancio O., Zhang H.P., Chen X., Lin C., Trinchese F., Puzzo D., Liu S., Hegde A., Yan S.F., Stern A., Luddy J.S., Lue L.F., Walker D.G., Roher A., Buttini M., Mucke L., Li W., Schmidt A.M., Kindy M., Hyslop P.A., Stern D.M. and Du Yan S.S. (2004). RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 23, 4096-4105.
3. Bell R.D. (2012). The imbalance of vascular molecules in Alzheimer's disease. J. Alzheimers Dis. 32, 699-709.
4. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J. and Kern W. (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334.
5. Bierhaus A. and Nawroth P.P. (2005). Posttranslational modification of lipoproteins--a fatal attraction in metabolic disease? J. Alzheimers Dis. 7, 315-317.
6. Bierhaus A. and Nawroth P.P. (2009). Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soli in inflammation, immune response and diabetes mellitus and its complications. Diabetologia 52, 2251-2263.
7. Bierhaus A., Hofmann M.A., Ziegler R. and Nawroth P.P. (1998). The AGE/RAGE pathway in vascular disease and diabetes mellitus. Part I: The AGE concept. Cardiovasc. Res. 37, 586-600.
8. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., Hong M., Luther T., Henle T., Kloting I., Morcos M., Hofmann M., Tritschler H., Weigle B., Kasper M., Smith M., Perry G., Schmidt A.M., Stern D.M., Haring H.U., Schleicher E. and Nawroth P.P. (2001). Diabetes-associated sustained activation of the transcription factor NF-κB. Diabetes 50, 2792-2809.
9. Bierhaus A., Humpert, P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M. and Nawroth P.P. (2005). Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83, 876-886.
10. Bierhaus A., Stern D.M. and Nawroth P.P. (2008). RAGE in inflammation: a new therapeutic target? Curr. Opin. Investig. Drugs 7, 985-991.
11. Bitel C.L., Kasinathan C., Kaswala R.H., Klein W.L. and Frederikse P.H. (2012). Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J. Alzheimers Dis. 32, 291-305.
12. Bjorklund N.L., Reese L.C., Sadagoparamanujam V.M., Ghirardi V., Woltjer R.L. and Taglialatela G. (2012). Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer's disease neuropathology. Mol. Neurodegener. 7, 23.
13. Blouet C., Liu S.M., Jo Y.H., Chua S. and Schwartz G.J. (2012). TXNIP in Agrp neurons regulates adiposity, energy expenditure, and central leptin sensitivity. J. Neurosci. 32, 9870-9877.
14. Blouet C. and Schwartz G.J. (2011). Nutrient-sensing hypothalamic TXNIP links nutrient excess to energy imbalance in mice. J. Neurosci. 31, 6019-6027.
15. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T. and De Felice F.G. (2012). An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Aβ oligomers. J. Clin. Invest. 122, 1339-1353.
16. Bourne K.Z., Ferrari D.C., Lange-Dohna C., Rossner S., Wood T.G. and Perez-Polo J.R. (2007). Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J. Neurosci. Res. 85, 1194-1204.
17. Breunig J.J., Guillot-Sestier M.V. and Town T. (2013). Brain injury, neuroinflammation and Alzheimer's disease. Front. Aging Neurosci. 5, 26.
18. Carnevale D., Mascio G., D'Andrea I., Fardella V., Bell R.D., Branchi I., Pallante F., Zlokovic B., Yan S.S. and Lembo G. (2012). Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60, 188-197.
19. Chen Z. and Zhong C. (2013). Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 108, 21-43.
20. Cheng Z., Tseng Y. and White M.F. (2010). Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 21, 589-598.
21. Cho H.J., Son S.M., Jin S.M., Hong H.S., Shin D.H., Kim S.J., Huh K. and Mook-Jung I. (2009). RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J. 23, 2639-2649.
22. Chutkow W.A., Birkenfeld A.L., Brown J.D., Lee H.Y., Frederick D.W., Yoshioka J., Patwari P., Kursawe R., Cushman S.W., Plutzky J., Shulman G.I., Samuel V.T. and Lee R.T. (2010). Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 59, 1424-1434.
23. Cotoi O.S., Duner P., Ko N., Hedblad B., Nilsson J., Bjorkbacka H. and Schiopu A. (2014). Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler. Thromb. Vasc. Biol. 34, 202-210.
24. Craft S. (2012). Alzheimer disease: insulin resistance and AD — extending the translational path. Nat. Rev. Neurol. 8, 360-362.
25. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D. and Gerton B. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29-38.
26. Crawford J.R., Bjorklund N.L., Taglialatela G. and Gomer R.H. (2012). Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer's disease neuropathology. Neurochem. Res. 37, 795-801.
27. Cullen K., Kocsi Z. and Stone J. (2006). Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol. Aging 27, 1786-1796.
28. Cunnane S., Nugent S., Roy M., Courchesne-Loyer A., Croteau E., Tremblay S., Castellano A., Pifferi F., Bocti C., Paquet N., Begdouri H., Bentourkia M., Turcotte E., Allard M., Barberger-Gateau P., Fulop T. and Rapoport S.I. (2011). Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 27, 3-20.
29. Daborg J., von Otter M., Sjolander A., Skoog I., Blennow K. and Zetterberg H. (2010). Association of the RAGE G82S polymorphism with Alzheimer's disease. J. Neural. Transm. 117, 861-867.
30. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T. and Klein W.L. (2007). Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptordependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282, 11590-11601.
31. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T. and Klein W.L. (2009). Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. USA 106, 1971-1976.
32. De Felice F.G. (2013). Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 123, 531-539.
33. De la Torre J.C. (2005). Is Alzheimer’s disease preceded by neurodegeneration or cerebral hypoperfusion? Ann. Neurol. 57, 783-784.
34. De Strooper B., Iwatsubo T. and Wolfe M.S. (2012). Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2, a006304.
35. Deane R. and Zlokovic B.V. (2007). Role of the blood brin barrier in the pathogenesys of Alzheimer's disease. Curr. Alzheimer Res. 4, 191-197.
36. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D. and Zlokovic B. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913.
37. Deane R., Bell R.D., Sagare A. and Zlokovic B.V. (2009). Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 8, 16-30.
38. Dickstein D.L., Walsh J., Brautigam H., Stockton S.D. Jr, Gandy S. and Hof P.R. (2010). Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt. Sinai J. Med. 77, 82-102.
39. Donahue J.E., Flaherty S.L., Johanson C.E., Duncan J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., Hovanesian V. and Stopa E.G. (2006). RAGE, LRP-1, and amyloidbeta protein in Alzheimer’s disease. Acta Neuropathol. (Berl.) 112, 405-415.
40. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Rossor M. and Brooks D.J. (2008). Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 32, 412-419.
41. Emanuele E., D'Angelo A., Tomaino C., Binetti G., Ghidoni R., Politi P., Bernardi L., Maletta R., Bruni A.C. and Geroldi D. (2005). Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62, 1734-1736.
42. Englund E. (2002). Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc. Dis. 13, 11-15.
43. Fang F., Lue L.F., Yan S., Xu H., Luddy J.S., Chen D., Walker D.G., Stern D.M., Yan S., Schmidt A.M., Chen J.X. and Yan S.S. (2010). RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 24, 1043-1055.
44. Fernando M.S., Simpson J.E., Matthews F., Brayne C., Lewis C.E., Barber R., Kalaria R.N., Forster G., Esteves F., Wharton S.B., Shaw P.J., O'Brien J.T. and Ince P.G.; MRC Cognitive Function and Ageing Neuropathology Study Group. (2006). White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 37, 1391-1398.
45. Ferreira N.E., Omae S., Pereira A., Rodrigues M.V., Miyakawa A.A., Campos L.C., Santos P.C., Dallan L.A., Martinez T.L., Santos R.D., Mill J.G., Krieger J.E. and Pereira A.C. (2012). Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. Atherosclerosis 221, 131-136.
46. Fetler L. and Amigorena S. (2005). Neuroscience. Brain under surveillance: the microglia patrol. Science 309, 392-393.
47. Firbank M.J., Wiseman R.M., Burton E.J., Saxby B.K., O'Brien J.T. and Ford G.A. (2007). Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. J. Neurol. 254, 713-721.
48. Fleming T.H., Humpert P.M., Nawroth P.P. and Bierhaus A. (2011). Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process. Gerontology 57, 435-443.
49. Forette F., Seux M.L., Staessen J.A., Thijs L., Babarskiene M.R., Babeanu S., Bossini A., Fagard R., Gil-Extremera B., Laks T., Kobalava Z., Sarti C., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y. and Birkenhager W.H.; Systolic Hypertension in Europe Investigators. (2002). The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162, 2046-2052.
50. Fotuhi M., Hachinski V. and Whitehouse P.J. (2009). Changing perspectives regarding late-life dementia. Nat. Rev. Neurol. 5, 649-658.
51. Freiherr J., Hallschmid M., Frey W.H. 2nd, Brunner Y.F., Chapman C.D., Holscher C., Craft S., De Felice F.G. and Benedict C. (2013). Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27, 505-514.
52. Fuhrmann M., Bittner T., Jung C.K., Burgold S., Page R.M., Mitteregger G., Haass C., LaFerla F.M., Kretzschmar H. and Herms J. (2010). Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 13, 411-413.
53. Gao T..L, Yuan X.T., Yang D., Dai H.L., Wang W.J., Peng X., Shao H.J., Jin Z.F. and Fu Z.J. (2012). Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury. J. Trauma Acute Care Surg. 72, 643-649.
54. Ginhoux F., Lim S., Hoeffel G., Low D. and Huber T. (2013). Origin and differentiation of microglia. Front. Cell. Neurosci. 7, 45.
55. Giunta B., Obregon D., Velisetty R., Sanberg P.R., Borlongan C.V. and Tan J. (2012). The immunology of traumatic brain injury: a prime target for Alzheimer's disease prevention. J. Neuroinflammation 9, 185.
56. Guglielmotto M., Aragno M., Tamagno E., Vercellinatto I., Visentin S., Medana C., Catalano M.G., Smith M.A., Perry G., Danni O., Boccuzzi G. and Tabaton M. (2010). AGEs/RAGE complex upregulates BACE1 via NF-kB pathway activation. Neurobiol. Aging 33, 196.e13-27
57. Haass C., Kaether C., Thinakaran G. and Sisodia S. (2012). Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270.
58. Hall E.D., Oostveen J.A., Dunn E. and Carter D.B. (1995). Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp. Neurol. 135, 17-27.
59. Hand L.E., Saer B.R., Hui S.T., Jinnah H.A., Steinlechner S., Loudon A.S. and Bechtold D.A. (2013). Induction of the metabolic regulator Txnip in fasting-induced and natural torpor. Endocrinology 154, 2081-2091.
60. Hardy J. and Selkoe D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
61. Hassid B.G., Nair M.N., Ducruet A.F., Otten M.L., Komotar R.J., Pinsky D.J., Schmidt A.M., Yan S.F. and Connolly E.S. (2009). Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia. J. Clin. Neurosci. 16, 302-306.
62. Hokama M., Oka S., Leon J., Ninomiya T., Honda H., Sasaki K., Iwaki T., Ohara T., Sasaki T., Laferla F.M., Kiyohara Y. and Nakabeppu Y. (2014). Altered expression of diabetes-related genes in alzheimer's disease brains: The hisayama study. Cereb. Cortex 24, 2476-2488.
63. Horie K., Miyata T., Yasuda T., Takeda A., Yasuda Y., Maeda K., Sobue G. and Kurokawa K. (1997). Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem. Biophys. Res. Commun. 236, 327-332.
64. Iadecola C., Park L. and Capone, C. (2009). Threats to the mind: aging, amyloid, and hypertension. Stroke 40, S40-S44.
65. Kalaria R.N. (2000). The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 21, 321-330.
66. Kalaria R.N., Akinyemi R. and Ihara M. (2012). Does vascular pathology contribute to Alzheimer changes? J. Neurol. Sci. 322, 141-147.
67. Kamide T., Kitao Y., Takeichi T., Okada A., Mohri H., Schmidt A.M., Kawano T., Munesue S., Yamamoto Y., Yamamoto H., Hamada J. and Hori O. (2012). RAGE mediates vascular injury and inflammation after global cerebral ischemia. Neurochem. Int. 60, 220-228.
68. Kern A. and Behl C. (2009). The unsolved relationship of brain aging and late-onset Alzheimer disease. Biochim. Biophys. Acta 1790, 1124-1232.
69. Kikuchi K., Tancharoen S., Ito T., Morimoto-Yamashita Y., Miura N., Kawahara K., Maruyama I., Murai Y. and Tanaka E. (2013). Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int. J. Mol. Sci. 14, 18899-18924.
70. Kim S.Y., Suh H.W., Chung J.W., Yoon S.R. and Choi I. (2007). Diverse functions of VDUP1 in cell proliferation, differentiation, and diseases. Cell. Mol. Immunol. 4, 345-351.
71. Kivipelto M., Helkala E.L., Hanninen T., Laakso M.P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J. and Nissinen A. (2001). Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 56, 1683-1689.
72. Kraus C., Rohde D., Weidenhammer C., Qiu G., Pleger S.T., Voelkers M., Boerries M., Remppis A., Katus H.A. and Most P. (2009). S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J. Mol. Cell. Cardiol. 47, 445-455.
73. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R. and Havlik R.J. (2000). Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 21, 49-55.
74. Leclerc E., Sturchler E. and Vetter S.W. (2010). The S100B/RAGE Axis in Alzheimer's Disease. Cardiovasc. Psychiatry. Neurol. 2010, 539581.
75. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M. and Ashe K.H. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
76. Lesne S., Kotilinek L. and Ashe K.H. (2008). Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151, 745-749.
77. Li S., Wang W., Wang C. and Tang Y.Y. (2010). Possible involvement of NO/NOS signaling in hippocampal amyloid-beta production induced by transient focal cerebral ischemia in aged rats. Neurosci. Lett. 470, 106-110.
78. Li J., Wang Y.J., Zhang M., Fang C.Q. and Zhou H.D. (2011). Cerebral ischemia aggravates cognitive impairment in a rat model of Alzheimer's disease. Life Sci. 89, 86-92.
79. Liu G., Yao L., Liu J., Jiang Y., Ma G., Genetic Environmental Risk for Alzheimer's disease (GERAD1) Consortium, Chen Z., Zhao B. and Li K. (2014). Cardiovascular disease contributes to Alzheimer's disease: evidence from large-scale genome-wide association studies. Neurobiol. Aging 35, 786-792.
80. Loske C., Gerdemann A., Schepl W., Wycislo M., Schnizel R., Palm D., Riederer P. and Munch G. (2000). Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur. J. Biochem. 267, 4171-4178.
81. Luchsinger J.A. (2012). Type 2 diabetes and cognitive impairment: linking mechanisms. J. Alzheimers Dis. 30, S185-S198.
82. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., Chen P.P., Hudspeth B., Chen C., Zhao Y., Vinters H.V., Frautschy S.A. and Cole G.M. (2009). Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29, 9078-9089.
83. Maxwell W.L., MacKinnon M.A., Stewart J.E. and Graham D.I. (2010). Stereology of cerebral cortex after traumatic brain injury matched to the Glasgow outcome score. Brain Res. 133, 139-160.
84. Mazarguil H., Leveque C., Bartnik D., Fantini J., Gouget T., Funke S.A., Willbold D. and Perrone L. (2012). A synthetic amino acid substitution of Tyr10 in Aβ peptide sequence yields a dominant negative variant in amyloidogenesis. Aging Cell 11, 530-541.
85. Mercier E., Boutin A., Lauzier F., Fergusson D.A., Simard J.F., Zarychanski R., Moore L., McIntyre L.A., Archambault P., Lamontagne F., Legare F., Randell E., Nadeau L., Rousseau F. and Turgeon A.F. (2013). Predictive value of S-100β protein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis. BMJ 346, f1757.
86. Mielke M.M., Savica R., Wiste H.J., Weigand S.D., Vemuri P., Knopman D.S., Lowe V. J, Roberts R.O., Machulda M.M., Geda Y.E., Petersen R.C and Jack C.R. Jr (2014). Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology 82, 70-76.
87. Mosher K.I. and Wyss-Coray T. (2014). Microglial dysfunction in brain aging and Alzheimer's disease. Biochem. Pharmacol. 88, 594-604.
88. Mosser D.M. and Edwards J.P. (2008). Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969.
89. Mousa S.A., Gallati C., Simone T., Dier E., Yalcin M., Dyskin E., Thangirala S., Hanko C. and Rebbaa A. (2009). Dual targeting of the antagonistic pathways mediated by Sirt1 and TXNIP as a putative approach to enhance the efficacy of anti-aging interventions. Aging 1, 412-424.
90. Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., Bendszus M., Rossetti G., Nawroth P.P., Bierhaus, A. and Schwaninger M. (2008). The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28, 12023-12031.
91. Muoio D. (2007). TXNIP links redox circuitry to glucose control. Cell Metab. 5, 412-414.
92. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Yamada S., Ueda Y. and Koide H. (2012). Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am. J. Med. Sci. 343, 46-51.
93. Nayak D., Roth T.L. and McGavern D.B. (2014). Microglia development and function. Annu. Rev. Immunol. 32, 367-402.
94. Origlia N., Bonadonna C., Rosellini A, Leznik E., Arancio O., Yan S.S. and Domenici L. (2010). Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. J. Nerosci. 30, 11414-11425.
95. Pantoni L. and Garcia J.H. (1995). The significance of cerebral white matter abnormalities 100 years after Binswanger’s report. Stroke 26, 1293-1301.
96. Parikh H., Carlsson E., Chutkow W., Johansson L., Storgaard H., Poulsen P., Saxena R., Ladd C., Schulze P., Mazzini M., Jensen C.B., Krook A., Bjornholm M., Tornqvist H., Zierath J.R., Ridderstrale M., Altshuler D., Lee R.T., Vaag A., Groop L.C. and Mootha V.K. (2007). TXNIP regulates peripheral glucose metabolism in humans. PloS Med. 4, e158.
97. Paris D., Patel N., Quadros A., Linan M., Bakshi P., Ait-Ghezala G. and Mullan M. (2007). Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci. Lett. 415, 11-16.
98. Perrone L., Devi T.S., Hosoya K.C., Terasaki T. and Singh L.P. (2009). Thioredoxin Interacting Protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J. Cell. Physiol. 221, 262-272
99. Perrone L., Mothes E., Vignes M., Mockel A., Figueroa C., Miquel M.C., Maddelein M.L. and Faller P. (2010). Copper transfer from Cu-Abeta to human serum albumin inhibits aggregation, radical production and reduces Abeta toxicity. Chembiochem 11, 110-118.
100. Perrone L., Sbai O., Nawroth P.P. and Bierhaus A. (2012). The complexity of sporadic alzheimer's disease pathogenesis: The role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int. J. Alzheimers Dis. 2012, 734956-734966.
101. Peters R., Beckett N., Forette F., Tuomilehto J., Clarke R., Ritchie C., Waldman A., Walton I., Poulter R., Ma S., Comsa M., Burch L., Fletcher A. and Bulpitt C.; HYVET investigators. (2008). Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7, 683-689.
102. Peters R., Beckett N., Forette F., Tuomilehto J., Ritchie C., Walton I., Waldman A., Clarke R., Poulter R., Fletcher A. and Bulpitt C. (2009). Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a crosssectional analysis. Int. Psychogeriatr. 21, 359-368.
103. Picone P., Giacomazza D., Vetri V., Carrotta R., Militello V., San Biagio P.L. and Di Carlo M. (2011). Insulin-activated Akt rescues Aβ oxidative stress-induced cell death by orchestrating molecular trafficking. Aging Cell 10, 832-843.
104. Pluta R., Furmaga-Jabłońska W., Maciejewski R., Ułamek-Kozioł M. and Jabłoński M. (2013). Brain ischemia activates β-and γ-secretase cleavage of amyloid precursor protein: significance in sporadic Alzheimer's disease. Mol. Neurobiol. 47, 425-434.
105. Popa-Wagner A., Schroder E., Walker L.C. and Kessler C. (1998). Betaamyloid precursor protein and ss-amyloid peptide immunoreactivity in the rat brain after middle cerebral artery occlusion: effect of age. Stroke 29, 2196-2202.
106. Qi J.P., Wu H., Yang Y., Wang D.D., Chen Y.X., Gu Y.H. and Liu T. (2007). Cerebral ischemia and Alzheimer’s disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. J. Alzheimers Dis. 12, 335-341.
107. Qiu C., Kivipelto M. and von Strauss E. (2009). Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 11, 111-128.
108. Rahmadi A., Stener N. and Munch, G. (2011). Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. Clin. Chem. Lab. Med. 49, 385-391.
109. Raivich G. (2005). Like cops on the beat: the active role of resting microglia. Trends Neurosci. 28, 571-573.
110. Reddy V.P., Zhu X., Perry G. and Smith M.A. (2009). Oxidative stress in diabetes and Alzheimer's disease. J. Alzheimers Dis. 16, 763-774.
111. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P. and Craft S. (2008). Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
112. Saraiva L.M., Seixas da Silva G.S., Galina A., da-Silva W.S., Klein W.L., Ferreira S.T. and De Felice F.G. (2012). Amyloid-β triggers the release of neuronal hexokinase 1 from mitochondria. PloS One 15, e15230.
113. Sastre M., Richardson J.C., Gentleman S.M. and Brooks D.J. (2011). Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr. Alzheimer Res. 8, 132-141.
114. Sato N., Takeda S., Uchio-Yamada K., Ueda H., Fujisawa T., Rakugi H. and Morishita R. (2011). Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr. Aging Sci. 4, 118-127.
115. Sbai O., Devi T.S., Melone M.A., Feron F., Khrestchatisky M., Singh L.P. and Perrone L. (2010). RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion. J. Cell Sci. 123, 4332-4339.
116. Schalkwijk C.G., Lieuw-a-Fa M., van Hinsbergh V.W. and Stehouwer C.D. (2002). Pathophysiological role of Amadori-glycated proteins in diabetic microangiopathy. Semin. Vasc. Med. 2, 191-197.
117. Schmidt A.M., Sahagan B., Nelson R.B., Selmer J., Rothlein R. and Bell J.M. (2009). The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr. Opin. Investig. Drugs 10, 672-680.
118. Selkoe D.J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113.
119. Serrano F. and Klann E. (2004). Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res. Rev. 3, 431-443.
120. Skoog I., Lithell H., Hansson L., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A. and SCOPE S. Group. (2005). Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on Cognition and Prognosis in the Elderly (SCOPE). Am. J. Hypertens. 18, 1052-1059.
121. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A. and Markesbery W.R. (1997). Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817.
122. Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D. and Munch G. (2011). Advanced glycation endproducts and their receptor RAGE In Alzheimer's disease. Neurobiol. Aging 32, 763-777.
123. Steen E., Terry B.M., Rivera E.J., Cannon J., Neely T.R., Tavares R., Xu XJ, Wands J.R. and de la Monte S.M. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease — is this type 3 diabetes? J. Alzheimers Dis. 7, 63-80.
124. Stewart R., Xue Q.L., Masaki K., Petrovitch H., Ross G.W., White L.R. and Launer L.J. (2009). Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 54, 233-240.
125. Stitt A.W. (2001). Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J. Ophthalmol. 85, 746-753.
126. Streit W.J., Xue Q.S., Braak H. and del Tredici K. (2014). Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain. Glia 62, 96-105.
127. Sullivan K.A. and Feldman E.L. (2005). New developments in diabetic neuropathy. Curr. Opin. Neurol. 18, 586-590.
128. Sun X., He G., Qing H., Zhou W., Dobie F., Cai F., Staufenbiel M., Huang L.E. and Song W. (2006). Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl. Acad. Sci. USA 103, 18727-18732.
129. Takeda S., Sato N., Ogihara T. and Morishita R. (2008). The reninangiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential. Front. Biosci. 13, 2253-2265.
130. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H. and Morishita R. (2010). Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. USA 107, 7036-7041.
131. Turturro F., Friday E. and Welbourne T. (2007). Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxininteracting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC cancer 7, 96.
132. Valente T., Gella A., Fernandez-Busquets X., Unzeta M. and Durany N. (2010). Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol. Dis. 37, 67-76.
133. Valenzuela M., Esler M., Ritchie K. and Brodaty H. (2012). Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention. Transl. Psychiatry 2, e107.
134. van Straaten E.C., Harvey D., Scheltens P., Barkhof F., Petersen R.C., Thal L.J., Jack C.R. Jr, DeCarli C. and Alzheimer's Disease Cooperative Study Group. (2008). Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J. Neurol. 255, 1302-1308.
135. Vignini A., Giulietti A., Nanetti L., Raffaelli F., Giusti L., Mazzanti L. and Provinciali L. (2013). Alzheimer's disease and diabetes: new insights and unifying therapies. Curr. Diabetes Rev. 9, 218-227.
136. Vitek M.P., Bhattacharaya K., Glendenig J.M., Stopa E., Vlassara H., Bucala R., Manoque K. and Cerami A. (1994). Advanced glycation endproducts contribute to amyloidosis In Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 4766-4770.
137. Wang X., Yu S., Hu J.P., Wang C.Y., Wang Y., Liu H.X. and Liu Y.L. (2014). Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-κB pathway. Int. J. Neurosci. Dec 12. 124, 601-608.
138. Webster S.J., Mruthinti S., Hill W.D., Buccafusco J.J. and Terry A.V. Jr (2012). An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease. Neuromolecular Med. 14, 119-130.
139. Wen Y., Onyewuchi O., Yang S., Liu R. and Simpkins J.W. (2004). Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res. 1009, 1-8.
140. Wu N., Zheng B., Shaywitz A., Dagon Y., Tower C., Bellinger G., Shen C.H., Wen J., Asara J., McGraw T.E., Kahn B.B. and Cantley L.C. (2013). AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1. Mol. Cell 49, 1167-1175
141. Xiong X.X., Gu L.J., Shen J., Kang X.H., Zheng Y.Y., Yue S.B. and Zhu S.M. (2014). Probenecid protects against transient focal cerebral ischemic injury by inhibiting HMGB1 release and attenuating AQP4 expression in mice. Neurochem. Res. 39, 216-224.
142. Xu Y., Toure F., Qu W., Lin L., Song F., Shen X., Rosario R., Garcia J., Schmidt A.M. and Yan S.F. (2010). Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J. Biol. Chem. 285, 23233-23240.
143. Xu G., Chen J., Jing G. and Shalev A. (2012). Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes 61, 848-856.
144. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D. and Schmidt A.M. (1996). RAGE and amyloid-beta neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
145. Yan S.D., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godma G.C., Stern D.M. and Schmidt A.M. (1997). Amiloid-beta peptide-Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophagecolony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. USA 94, 5296-5301.
146. Yan S.D., Roher A., Chaney M., Zlokovic B., Schmidt A.M. and Stern D.M. (2000). Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim. Biophys. Acta 1502, 145-157.
147. Yan S.D., Bierhaus A., Nawroth P.P. and Stern D.M. (2009a). RAGE and Alzheimer's disease: a progression factor for amyloid-betainduced cellular perturbation? J. Alzheimers Dis. 16, 833-843.
148. Yan S.F., Ramasamy R. and Schmidt A.M. (2009b). The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert. Rev. Mol. Med. 11, e9.
149. Yan S.S., Chen D., Yan S., Guo L., Du H. and Chen J.X. (2012). RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Front. Biosci. (Schol Ed) 4, 240-250.
150. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A. and Klein W.L. (2008). Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 22, 246-260.
151. Zitman-Gal T., Green J., Pasmanik-Chor M., Oron-Karni V. and Bernheim J. (2010). Endothelial pro-atherosclerotic response to extracellular diabetic-like environment: possible role of thioredoxininteracting protein. Nephrol. Dial. Transplant. 25, 2141-2149.
152. Zitman-Gal T., Golan E., Green J., Bernheim J. and Benchetrit S. (2012). Vitamin D receptor activation in a diabetic-like environment: potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways. J. Steroid Biochem. Mol. Biol. 132, 1-7.